Part of Replimune
Clinical Trials
18
11 active
Approvals
0
Total approvals
Agencies
0
Regulatory bodies
Founded
N/A
Active, not recruiting
11
61.1%
Recruiting
4
22.2%
Terminated
1
5.6%
Unknown
1
5.6%
Withdrawn
1
5.6%
No approval data available
- The FDA has approved Replimune's oncolytic immunotherapy Tudriqev for unresectable advanced melanoma that has progressed after PD-1 immunotherapy. - Tudriqev, formerly known as RP1, is engineered to selectively target and destroy cancer cells and is the second oncolytic virus approved. - Both approved oncolytic viruses are engineered live attenuated HSV-1 vectors encoding GM-CSF and a fusogenic GALV-GP-R glycoprotein.
- The FDA approved Replimune's injected viral therapy Tudriqev for advanced melanoma after previously rejecting it twice over efficacy concerns. - Tudriqev is designed for use in combination with the checkpoint inhibitor nivolumab (Opdivo) in patients with advanced melanoma. - The approval followed White House intervention and a 10–3 vote by an FDA advisory panel in favor of the drug. - Replimune must conduct a confirmatory study as a condition of the accelerated approval.
- Multiple biotechnology companies including UniQure, Biohaven, and Capricor have faced unexpected FDA reversals on previously agreed-upon evidence requirements for drug approvals since July 2024. - UniQure's Huntington's disease gene therapy AMT-130, which showed 75% disease slowing in pivotal trials, had its biologics license application timeline thrown into uncertainty after FDA changed its stance on acceptable evidence. - The regulatory instability coincides with significant leadership changes at FDA, with the Center for Drug Evaluation and Research changing hands four times since early 2025 and philosophical differences emerging between current and previous FDA leadership. - Industry analysts suggest these reversals may signal a shift toward stricter regulatory standards, requiring more compelling risk-benefit profiles despite companies having aligned with FDA on trial designs and statistical analyses.
- Krystal Biotech has discontinued its Phase I/II OPAL-1 study of KB707, a viral immunotherapy for melanoma, citing heightened regulatory uncertainty following the FDA's rejection of Replimune's similar therapy RP1. - Both KB707 and RP1 use modified herpes simplex virus type 1 vectors to trigger immune responses against tumors, but the FDA's controversial rejection of RP1 has complicated accelerated approval pathways for this drug class. - The company is now focusing on an inhaled version of KB707 for non-small cell lung cancer, which showed a 36% objective response rate in heavily pretreated patients and has secured an FDA End of Phase II meeting for October. - Over 20 melanoma experts have challenged the FDA's rejection of RP1 in an open letter, arguing that the agency's concerns about patient population heterogeneity actually better represent real-world treatment scenarios.
- Recent FDA complete response letters for Replimune's RP1 and Capricor's CAP-1002 underscore increasing regulatory emphasis on analytical validation, tech transfer execution, and manufacturing controls in immunotherapy development. - Despite following FDA guidance throughout development, both companies received unexpected rejections, with 74% of CRLs issued from 2020 to 2024 citing quality or manufacturing deficiencies. - Industry experts warn that analytical methods and tech transfer plans that pass early scrutiny often collapse under commercial-scale expectations, requiring CMC rigor to be treated as front-line regulatory strategy. - The FDA's heightened scrutiny reflects evolving standards for biologics and advanced therapies, demanding robust manufacturing control strategies and comprehensive CMC data to ensure consistency, safety, and efficacy.
- The FDA rejected Replimune's melanoma drug in a complete response letter, citing inadequate single-arm study design and patient enrollment differences as key concerns. - The agency questioned whether the single-arm study provided substantial evidence of effectiveness and raised issues with the company's confirmatory trial design. - Analysts interpret the rejection as evidence of changing FDA approval standards, with Replimune CEO expressing surprise at the decision given prior agency meetings. - The rejection highlights the evolving regulatory landscape for oncology drug approvals, particularly for single-arm studies in melanoma treatment.
- The oncolytic virus cancer therapy market is experiencing robust growth with over 120 companies actively developing 125+ pipeline therapies, representing a significant expansion in this therapeutic segment. - The global market for oncolytic virus immunotherapy was valued at $156.8 million in 2024 and is projected to reach $429.1 million by 2030, growing at a CAGR of 18.3%. - Several promising candidates are advancing through late-stage clinical trials, including Olvi-Vec in Phase III for platinum-resistant ovarian cancer and CG0070 in Phase III for non-muscle invasive bladder cancer. - Recent breakthroughs in synthetic biology and vector engineering are enhancing the safety, selectivity, and immune-stimulatory capabilities of oncolytic viruses through genetic modifications and combination protocols.
• Replimune's BLA for RP1 (vusolimogene oderparepvec) plus nivolumab in advanced melanoma is proceeding on schedule with a PDUFA date of July 22, 2025, following completed manufacturing inspections and late cycle review. • The company has fully established its commercial infrastructure ahead of potential launch, targeting approximately 13,000 annual U.S. patients who progress on PD-1 treatment, with an estimated 80% eligible for RP1 therapy. • Replimune maintains a strong financial position with $483.8 million in cash, cash equivalents and short-term investments as of March 31, 2025, providing runway into Q4 2026 to support commercialization efforts.
• Replimune has initiated two clinical trials for RP2, an oncolytic immunotherapy, targeting metastatic uveal melanoma and hepatocellular carcinoma. • The RP2-202 trial will evaluate RP2 in combination with nivolumab for patients with metastatic uveal melanoma, a cancer with limited treatment options. • The RP2-003 trial will assess RP2 combined with atezolizumab and bevacizumab for patients with advanced hepatocellular carcinoma (HCC). • RP2 is derived from Replimune's RP1, engineered from herpes simplex virus to enhance tumor cell death and stimulate systemic anti-tumor immune response.
- The FDA has granted priority review to Replimune's BLA for RP1 in combination with nivolumab for advanced melanoma, setting a PDUFA action date of July 22, 2025. - The BLA is supported by data from the IGNYTE trial, which evaluated RP1 plus nivolumab in patients with anti-PD-1 failed melanoma. - RP1 is a novel oncolytic immunotherapy based on a modified herpes simplex virus, designed to maximize tumor killing and stimulate an anti-tumor immune response. - The ongoing Phase 3 IGNYTE-3 trial is assessing the combination in patients who have progressed on or are ineligible for anti-CTLA-4 therapies.
